Center for Infectious Disease Dynamics, Departments of Biology and Entomology, Pennsylvania State University, University Park, Pennsylvania 16827, USA.
Evolution. 2010 Oct;64(10):2952-68. doi: 10.1111/j.1558-5646.2010.01068.x. Epub 2010 Aug 19.
A major determinant of the rate at which drug-resistant malaria parasites spread through a population is the ecology of resistant and sensitive parasites sharing the same host. Drug treatment can significantly alter this ecology by removing the drug-sensitive parasites, leading to competitive release of resistant parasites. Here, we test the hypothesis that the spread of resistance can be slowed by reducing drug treatment and hence restricting competitive release. Using the rodent malaria model Plasmodium chabaudi, we found that low-dose chemotherapy did reduce competitive release. A higher drug dose regimen exerted stronger positive selection on resistant parasites for no detectable clinical gain. We estimated instantaneous selection coefficients throughout the course of replicate infections to analyze the temporal pattern of the strength and direction of within-host selection. The strength of selection on resistance varied through the course of infections, even in untreated infections, but increased immediately following drug treatment, particularly in the high-dose groups. Resistance remained under positive selection for much longer than expected from the half life of the drug. Although there are many differences between mice and people, our data do raise the question whether the aggressive treatment regimens aimed at complete parasite clearance are the best resistance-management strategies for humans.
抗药性疟原虫在人群中传播速度的一个主要决定因素是具有抗药性和敏感性的寄生虫在同一宿主中共存的生态学。药物治疗通过消除药物敏感的寄生虫,可以显著改变这种生态学,从而导致抗药性寄生虫的竞争释放。在这里,我们通过减少药物治疗从而限制竞争释放,来检验抗药性传播可以被减缓的假设。我们使用啮齿动物疟疾模型 Plasmodium chabaudi 进行研究,发现低剂量化疗确实可以减少竞争释放。更高的药物剂量方案对耐药寄生虫施加了更强的正向选择,但没有明显的临床获益。我们在重复感染的过程中估计了瞬时选择系数,以分析宿主内选择的强度和方向的时间模式。即使在未治疗的感染中,耐药性的选择强度也会随着感染的进程而变化,但在药物治疗后立即增加,尤其是在高剂量组中。耐药性在药物半衰期之外的很长一段时间内仍处于正向选择之中。尽管老鼠和人类之间存在许多差异,但我们的数据确实提出了一个问题,即针对完全清除寄生虫的积极治疗方案是否是人类对抗耐药性的最佳管理策略。